Oral Presentation


Title: Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL
Abstract #: 285
Session: 618. Acute Lymphoblastic Leukemia: Preclinical Models
Date and Time: Monday, December 8, 2014: 7:30 AM PT
Location: West Building, 3002-3004 (Moscone Center)

Poster Presentations


Title: VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo
Abstract #: 982
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Date and Time: Saturday, December 6, 2014, 5:30 PM-7:30 PM PT>
Location: North Building, Hall E (Moscone Center)


Title: Proline-Rich Tyrosine Kinase (PYK2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM
Abstract #: 2101
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Date and Time: Saturday, December 6, 2014, 5:30 PM-7:30 PM PT
Location: West Building, Level 1 (Moscone Center)


Title: Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death
Abstract #: 2081
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Date and Time: Saturday, December 6, 2014, 5:30 PM-7:30 PM PT
Location: West Building, Level 1 (Moscone Center)


Title: PYK2 Inhibitors Sensitize Hypoxia-Induced Drug Resistant Multiple Myeloma Cell
Abstract #: 4704
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III
Date and Time: Monday, December 8, 2014, 6:00 PM-8:00 PM PT
Location: West Building, Level 1 (Moscone Center)

The accepted abstracts listed above are now available online on the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/